1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1134-or ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von PETTER BJORNSTAD und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Tirzepatide (TZP) demonstrated improvements in glycemic control and BMI in participants with youth-onset type 2 diabetes (YT2D) in SURPASS-PEDS. TZP impact on glomerular hyperfiltration, an early disease marker affecting 24% of YT2D, was not previously assessed. This analysis examined changes in estimated glomerular filtration rate (eGFR) and hyperfiltration status with TZP treatment.
Methods
TZP vs PBO was assessed for 30 weeks in participants 10 to <18 years old with YT2D on metformin and/or basal insulin. Participants received TZP 5 mg (n=32), 10 mg (n=33) or PBO (n=34). eGFR was calculated using Zappitelli creatinine-cystatin C equation; hyperfiltration was defined as eGFR ≥126.8 mL/min/1.73 m². Change in eGFR (MMRM) and shifts in hyperfiltration status (Fisher’s exact test) were assessed.
Results
At baseline, mean age was 14.7 years old and 18% of participants exhibited hyperfiltration (mean eGFR 142 vs 104 mL/min/1.73m2 in normofiltration). TZP treatment led to a reduction in eGFR at Week 30, with greater than two-times reduction in participants with baseline hyperfiltration (Table 1). The proportion of participants with hyperfiltration decreased in pooled TZP (18.6% to 5.5%) and increased in PBO (16.1% to 21.9%, p<0.05, TZP vs PBO).
Conclusion
In the SURPASS-PEDS trial, treatment with tirzepatide was associated with a mean decrease in eGFR, primarily ascribed to attenuation of glomerular hyperfiltration.
Trial registration
ClinicalTrials.gov (NCT05260021). Disclosure P. Bjornstad: Consultant; Current; Bayer AG, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk. T.S. Hannon: None. J.M. Maldonado: Employee; Current; Eli Lilly and Company. K. Ranta: Employee; Current; Eli Lilly and Company. K. Pamidipati: None. H. Patel: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. B. Bergman: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. Funding Eli Lilly and Company
Zitieren
APA
BJORNSTAD, P., HANNON, T. S., MALDONADO, J. M., RANTA, K., PAMIDIPATI, K. C., PATEL, H., & BERGMAN, B. (2026). 1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1134-or
Vancouver
BJORNSTAD P, HANNON TS, MALDONADO JM, RANTA K, PAMIDIPATI KC, PATEL H, et al. 1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1134-or
BibTeX
@article{BJORNSTAD2026,
author = {BJORNSTAD, PETTER and HANNON, TAMARA S. and MALDONADO, JUAN M. and RANTA, KARI and PAMIDIPATI, KARTHIK CHANDRASEKHAR and PATEL, HIREN and BERGMAN, BRANDON},
title = {1134-OR: Reduction in Glomerular Hyperfiltration with Tirzepatide in Youth-Onset T2D},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1134-or}
}
EUVIMED